Edesa Biotech to Present at Guggenheim Healthcare Innovation Conference

Edesa Biotech (Nasdaq: EDSA) will participate in Guggenheim’s 3rd Annual Healthcare Innovation Conference in Boston on November 9–11, 2026.

Rhea-AI Summary

Edesa Biotech (Nasdaq: EDSA) will participate in Guggenheim’s 3rd Annual Healthcare Innovation Conference in Boston on November 9–11, 2026. Chief Executive Officer Par Nijhawan will present a fireside chat on November 9 at 3:00 pm ET, and management will hold one-on-one investor meetings.

Key Terms

monoclonal antibody, vitiligo, allergic contact dermatitis, ards

4 terms

monoclonal antibody medical

"an anti-CXCL10 monoclonal antibody candidate"

A monoclonal antibody is a laboratory-made protein designed to recognize and attach to a specific target in the body, such as a disease-causing substance or cell. It functions like a highly precise lock-and-key tool, helping to treat or detect illnesses. For investors, companies developing monoclonal antibodies can represent promising opportunities in the healthcare sector, especially as these treatments often address unmet medical needs.

vitiligo medical

"as a therapy for vitiligo"

An autoimmune skin condition in which the body’s immune system destroys pigment-producing cells, causing irregular white patches on the skin; think of it like paint fading in isolated areas. It matters to investors because the condition creates demand for medical treatments, topical products and cosmetic coverage, so advances in therapies, clinical trial results or regulatory approvals can alter potential market size and a company’s future revenue prospects.

allergic contact dermatitis medical

"moderate-to-severe chronic Allergic Contact Dermatitis (ACD)"

Allergic contact dermatitis is a skin reaction that happens when a person’s immune system becomes sensitized to a substance and then reacts with redness, itching, blisters or a rash after skin contact. Think of the skin as a smoke alarm that, once triggered by a particular chemical, will react strongly each time it encounters it. For investors it matters because outbreaks, product recalls, regulatory restrictions or rising treatment costs can hurt sales, trigger liability claims, affect supply chains and change healthcare or workplace expense forecasts.

ards medical

"as a treatment for ARDS, a life-threatening form of respiratory failure"

Acute respiratory distress syndrome (ARDS) is a sudden, severe failure of the lungs where fluid and inflammation prevent oxygen from getting into the bloodstream, like heavy wet balloons that won’t inflate properly. It matters to investors because ARDS represents a serious unmet medical need that drives demand for new therapies, influences clinical trial size and risk, affects regulatory scrutiny and reimbursement, and can significantly impact the valuation of companies developing treatments or diagnostics.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

TORONTO, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq: EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today announced that management will participate in Guggenheim’s 3rd Annual Healthcare Innovation Conference, including a fireside chat and one-on-one investor meetings.

Conference Details

Dates: November 9–11, 2026
Location: Boston, Massachusetts
Presenter: Par Nijhawan MD, FRCPC, AGAF, Chief Executive Officer
Fireside Chat: Monday, November 9, 2026, at 3:00 pm ET

Investors interested in meeting with management during the conference may contact their Canaccord representative or the company directly at investors@edesabiotech.com.

About Edesa Biotech, Inc.

Edesa Biotech, Inc. (Nasdaq: EDSA) is a clinical-stage biopharmaceutical company developing innovative ways to treat inflammatory and immune-related diseases. Its clinical pipeline is focused on two therapeutic areas: Medical Dermatology and Respiratory. In Medical Dermatology, Edesa is developing EB06, an anti-CXCL10 monoclonal antibody candidate, as a therapy for vitiligo, a common autoimmune disorder that causes skin to lose its color in patches. Its medical dermatology assets also include EB01 (1.0% daniluromer cream), a Phase 3-ready asset developed for use as a potential therapy for moderate-to-severe chronic Allergic Contact Dermatitis (ACD). The company’s most advanced Respiratory drug candidate is paridiprubart, which is being evaluated in a U.S. government-funded platform study as a treatment for ARDS, a life-threatening form of respiratory failure. The paridiprubart program has been the recipient of two funding awards from the Government of Canada to support the further development of this asset. Sign up for news alerts. Connect with us on X and LinkedIn.

Edesa Forward-Looking Statements

This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," "may," "will," "would," "could," "should," "might," "potential," or "continue" and variations or similar expressions. Readers should not unduly rely on these forward-looking statements, which are not a guarantee of future performance. There can be no assurance that forward-looking statements will prove to be accurate, as all such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the forward-looking statements. Such risks include: the ability of Edesa to obtain regulatory approval for or successfully commercialize any of its product candidates, the risk that access to sufficient capital to fund Edesa's operations may not be available or may be available on terms that are not commercially favorable to Edesa, the risk that Edesa's product candidates may not be effective against the diseases tested in its clinical trials, the risk that Edesa fails to comply with the terms of license agreements with third parties and as a result loses the right to use key intellectual property in its business, Edesa's ability to protect its intellectual property, the timing and success of submission, acceptance and approval of regulatory filings, and the impacts of public health crises. Many of these factors that will determine actual results are beyond the company's ability to control or predict. For a discussion of further risks and uncertainties related to Edesa's business, please refer to Edesa's public company reports filed with the U.S. Securities and Exchange Commission and the British Columbia Securities Commission. All forward-looking statements are made as of the date hereof and are subject to change. Except as required by law, Edesa assumes no obligation to update such statements.

Contact
Gary Koppenjan
Edesa Biotech, Inc.
investors@edesabiotech.com